Macter International : Financial Results for the Quarter Ended March 31, 2023
April 18, 2023 at 01:03 pm IST
Share
Ref: PSX-23/05
April 18, 2023
The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building,
Stock Exchange Road,
Karachi
Subject: Financial Results for the period ended March 31, 2023
مكيلع ملاسلا
We have to inform you that the Board of Directors of our Company in their meeting held on April 18, 2023 at 11:00 am at Karachi recommended the following:
(i)
CASH DIVIDEND
:
NIL
(ii)
BONUS SHARES
:
NIL
(iii)
RIGHT SHARES
:
NIL
(iv)
ANY OTHER ENTITLEMENT/CORPORATE ACTION
:
NIL
(v)
ANY OTHER PRICE-SENSITIVE INFORMATION
:
NIL
The financial results of the Company are enclosed herewith.
The Quarterly Report of the Company for the period ended March 31, 2023 will be transmitted through PUCARS separately, within the specified time.
Yours truly,
For and on behalf of
Macter International Limited
Company Secretary
<<1 of 3>>
2
MACTER INTERNATIONAL LIMITED
UN-CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE PERIOD ENDED MARCH 31, 2023
NINE MONTHS ENDED
QUARTER ENDED
MARCH 31,
MARCH 31,
MARCH 31,
MARCH 31,
2023
2022
2023
2022
NOTE
........................ (RUPEES IN '000)
Turnover
5,209,642
4,004,401
1,430,392
1,453,175
Cost of sales
(3,042,508)
(2,199,664)
(813,149)
(788,821)
Gross profit
2,167,134
1,804,737
617,243
664,354
Distribution costs
(1,407,594)
(1,096,203)
(439,799)
(376,406)
Administrative expenses
(266,847)
(199,959)
(82,120)
(67,827)
Other expenses
(40,554)
(39,293)
(8,518)
(17,201)
Other income
53,132
24,432
24,864
4,299
(1,661,863)
(1,311,023)
(505,573)
(457,135)
Operating profit
505,271
493,714
111,670
207,219
Financial charges
12.2
(32,485)
(31,250)
(12,364)
(4,769)
Profit before taxation
472,786
462,464
99,306
202,450
Taxation
17
(153,799)
(123,951)
(29,596)
(60,160)
Net profit for the period
318,987
338,513
69,710
142,290
……………………………... (RUPEES)………………………………
(Re-stated)
(Re-stated)
Basic and diluted earnings per share
6.96
7.66
1.52
3.22
The annexed notes from 1 to 21 form an integral part of these unconsolidated condensed interim financial statements.
________________________
______________________
______________________
CHIEF FINANCIAL OFFICER
CHIEF EXECUTIVE
DIRECTOR
<<2 of 3>
>
2
MACTER INTERNATIONAL LIMITED
CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED)
FOR THE PERIOD ENDED MARCH 31, 2023
NINE MONTHS ENDED
QUARTER ENDED
MARCH 31,
MARCH 31,
MARCH 31,
MARCH 31,
2023
2022
2023
2022
NOTE
........................
(RUPEES IN '000)
Turnover
5,413,309
4,218,075
1,502,642
1,528,243
Cost of sales
(3,141,415)
(2,296,573)
(848,901)
(823,897)
Gross profit
2,271,894
1,921,502
653,741
704,346
Distribution costs
(1,529,780)
(1,227,825)
(483,778)
(423,960)
Administrative expenses
(269,796)
(203,332)
(83,045)
(69,130)
Other expenses
(40,554)
(39,293)
(8,518)
(17,201)
Other income
53,144
24,432
24,864
4,299
(1,786,986)
(1,446,018)
(550,477)
(505,992)
Operating profit
484,908
475,484
103,264
198,354
Financial charges
11.3 & 14.3
(40,348)
(36,209)
(15,491)
(6,214)
Profit before taxation
444,560
439,275
87,773
192,140
Taxation
17
(161,944)
(132,501)
(32,450)
(63,166)
Net profit for the period
282,616
306,774
55,323
128,974
.................
(RUPEES)
(Re-stated)
(Re-stated)
Basic and diluted earnings per share
6.17
6.94
1.21
2.92
The annexed notes from 1 to 21 form an integral part of these consolidated condensed interim financial statements.
Attributable to:
Owner of the Holding Company
289,539
312,763
57,139
130,177
Non- controlling interest
(6,923)
(5,989)
(1,816)
(1,203)
282,616
306,774
55,323
128,974
________________________
______________________
______________________
CHIEF FINANCIAL OFFICER
CHIEF EXECUTIVE
DIRECTOR
<<3 of 3>
>
Attachments
Original Link
Original Document
Permalink
Disclaimer
Macter International Ltd. published this content on 18 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 April 2023 07:32:12 UTC.
Macter International Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is to manufacture and market pharmaceutical products. The Companyâs business areas are contract manufacturing and branded generic formulations. It is a contract manufacturer for multinational companies, which offers a range of dosage forms: oral solids and liquids, parenteral (ampules and vials), topicals, metered dose inhalers, ear and eye drops. Its contract manufacturing clients include a number of blue-chip multinationals. The Company produces specialty products at its high-tech plant. These include solid and liquid oral dosage forms (tablets, capsules, syrups, suspensions and dry powder), injections (sterile liquid vials, sterile liquid ampoules and sterile dry powders), ointments and creams, drops and inhalers. Its manufacturing operations include formulation, vial filling, lyophilization and packaging of biological drugs.